|
BCC-Studie kleine Änderung an der BCC-Studie (01.05.2019): alt: "The study will be conducted as randomized, double blind and vehicle-controlled ( 4:1 ratio of verum (BF-200 ALA; Ameluz\u00ae) to vehicle (placebo)) clinical trial at 12 sites in the United States of America (US). Each site should randomize between 10 and 20 subjects. " neu: "The study will be conducted as randomized, double blind and vehicle-controlled ( 4:1 ratio of verum (BF-200 ALA; Ameluz\u00ae) to vehicle (placebo)) clinical trial at 15 sites in the United States of America (US). Each site should randomize between 10 and 20 subjects. " https://clinicaltrials.gov/ct2/show/record/NCT03573401?lupd_… https://clinicaltrials.gov/ct2/history/NCT03573401?B=3&A=4&C… |
|
| aus der Diskussion: | Biofrontera - Heiße Turnaround-Spekulation |
| Autor (Datum des Eintrages): | abgemeldet-486279 (19.05.19 09:35:36) |
| Beitrag: | 48,620 von 66,508 (ID:60597585) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |